Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BI 1026706 in Healthy Subjects and OA Patients
NCT02126826Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2014
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in osteoarthritis (OA) comparing Placebo with BI 1026706 (2 arms). Primary endpoint: Percentage of Subjects With Drug Related Adverse Events at 15 days. Started May 2014; status: completed.
02
Drugs
BI 1026706
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT02126826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02126826.